inflammatory bowel disease

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Clinical team alignment top priority for payersInvestment in resources that support clinicians and patients closer to the point of care may be the cure for what ails managed care executives.
Integrating pharmacy benefit, medical benefit cuts costsHere’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
Autoimmune disease + shingles = 50% increase in stroke riskPeople who have autoimmune diseases, including psoriasis, who get incident herpes zoster have a 50 percent increased stroke risk within a month of developing shingles, according to a new study.
Study to measure impact of MTM on outcomes for IBD patientsThe effectiveness of an inflammatory bowel disease (IBD) medication therapy management (MTM) patient fulfillment model and its impact on adherence compared to standard care will be evaluated in a new study.
IBD boosts melanoma riskPatients who have inflammatory bowel disease (IBD) are at an increased risk of melanoma, according to study results presented recently.
Isotretinoin not linked to IBD riskIsotretinoin does not appear to be linked to an increased risk of inflammatory bowel disease, researchers report.